3Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert Bourla, that landed in Pfizer’s cancer arsenal via a potential $6 billion deal in May, of which $1.2 billion was paid up front.
Pulmonary fibrosis is a potentially deadly lung disease characterized by progressive scarring and impaired lung function, with limited treatment options and a poor prognosis. Previous work found that targeting the activation, but not the production, of latent transforming growth factor 1 (TGF-β1) may offer therapeutic benefit in this condition.
Deepcure Inc. has nominated DC-15442, an oral selective STAT6 inhibitor, as its second development candidate. DC-15442 is designed to replicate the safety and efficacy of dupilumab, while offering an oral alternative to regular subcutaneous injections.
Lex Diagnostics Ltd. has submitted dual applications to the U.S. FDA seeking 510(k) clearance and CLIA waiver status for its Velo system, an ultra-fast point-of-care molecular diagnostics platform. The move comes after the recent news from Quidelortho Corp. that it intends to acquire Lex for $100 million following U.S. regulatory approval of the technology.
Insmed Inc.’s chair and CEO, Will Lewis, called the phase IIb trial of TPIP in pulmonary arterial hypertension a “clear and unequivocal success,” with analysts and investors wholeheartedly agreeing, as the company’s shares surged 28.7% June 10.
In progressive fibrotic diseases, which can occur in nearly all organs, myofibroblasts are activated to differentiate into proliferating fibroblastic cells that express genes that lead to deposition of extracellular matrix. The factors driving myofibroblast activation appear to be varied and complex, ranging from mechanical insults to inflammation, infection and cancer.
Seyltx Inc. has entered into an option agreement with Neurop Inc. for a portfolio of novel GluN2B antagonists. The compounds include NP-10679, which has completed phase I, and seven preclinical candidates.
It’s a good week to be working on drugs targeting STAT6. Kymera Therapeutics Inc.’s, KT-621, the first oral STAT6 degrader candidate to enter the clinic, surpassed expectations with impressive safety, pharmacokinetic and biomarker data from a phase I trial, while potential fast-followers from Nurix Therapeutics Inc. and Recludix Pharma Inc. advanced via respective partnerships with Sanofi SA.
Transpire Bio Inc. has signed an exclusive license agreement with Suzhou Intragrand Pharma Co. Ltd. for ITG-1052 (lenamilast), an investigational phosphodiesterase 4 (PDE4) inhibitor.
CSPC Pharmaceutical Group Ltd. on May 30 disclosed that the company was engaged in ongoing negotiations with unnamed, independent third parties regarding three license deals and collaborations that could total up to $5 billion combined.
RSS
